Laxxon Medical Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laxxon Medical Corporation - overview
Established
2017
Location
New York, NY, US
Primary Industry
Pharmaceuticals
About
Based in New York, US, and founded in 2017 in Switzerland by its CEO, Helmut Kerschbaumer, COO, Klaus Kuehne, and CSO, Achim Schneeberger, Laxxon Medical operates as a pharmaceutical company that provides additive manufacturing technology. In March 2022, Laxxon Medical raised an undisclosed amount of venture funding from new investor Evonik Venture Capital. Laxxon offers a patented SPID®-technology (Screen Printing Innovational Drug Technology) that helps pharmaceutical companies improve drug delivery systems. The company provides a three-dimensional screen-printing technology that produces time-release tablets that combine multiple ingredients in a single dose, hence increasing the production of tablets, film, implants, and transdermal patches.
The company plans to use the March 2022 funding to further develop its products while manufacturing them commercially.
Current Investors
Evonik Venture Capital, Bm-t
Primary Industry
Pharmaceuticals
Sub Industries
Business Support Services, Pharmaceutical Research & Development
Website
www.laxxonmedical.com
Verticals
3D Printing, HealthTech, Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.